PPARG and breast carcinoma: Consistently, treatment by LY294002, a specific PI3K inhibitor [21, 22] and troglitazone (TGZ), a PPARγ agonist, known to exhibit anti-proliferative activity in breast cancer cells [23–25] both achieved a significant reduction of H1 tyrosine phosphorylation in MCF7 (Figure 7, panel A and B).